loading page

Recombinant protein subunit COVID-19 Vaccine Induced Guillain-Barre Syndrome in an adolescent: A case report.
  • +2
  • Rachna Rohilla,
  • Ashish Kakkar,
  • Krishna Divyashree,
  • Ritin Mohindra,
  • Vikas Suri
Rachna Rohilla
Post Graduate Institute of Medical Education and Research

Corresponding Author:[email protected]

Author Profile
Ashish Kakkar
Post Graduate Institute of Medical Education and Research
Author Profile
Krishna Divyashree
Post Graduate Institute of Medical Education and Research
Author Profile
Ritin Mohindra
Department of Internal Medicine
Author Profile
Vikas Suri
Post Graduate Institute of Medical Education and Research
Author Profile

Abstract

Guillain- Barre Syndrome (GBS), an autoimmune neurological disease of peripheral nerves has been causally associated with COVID-19 vaccination in adults. However, no such report has been published so far in children. We describe a 13-year old female child who presented to emergency department with complaints of bilateral upper limb, lower limb and truncal weakness over three days following first dose of recombinant protein subunit COVID-19 vaccine (Corbevax). Clinical examination and nerve conduction studies showed pure motor axonal polyneuropathy with absent compound muscle action potential (CMAP) in all sampled nerves of upper and lower limbs which was consistent with the diagnosis of GBS after ruling out possible alternative aetiologies. A temporal association between first dose of protein subunit COVID-19 vaccine administered a day prior and symptom onset was noted. The causality assessment using World Health Organization (WHO) tool for adverse event following immunization (AEFI) assessment indicated vaccine-product related reaction categorized as A1. Patient’s clinical condition improved after seven sessions of plasmapheresis. The purpose of this report is to create awareness among the health care professionals about COVID-19 vaccine induced GBS in children as early diagnosis and management can be critical in avoiding complications and improving patient outcomes.
07 Jun 2022Submitted to British Journal of Clinical Pharmacology
09 Jun 2022Submission Checks Completed
09 Jun 2022Assigned to Editor
09 Jun 2022Reviewer(s) Assigned
27 Jun 2022Review(s) Completed, Editorial Evaluation Pending
30 Jun 2022Editorial Decision: Revise Minor
30 Jun 20221st Revision Received
01 Jul 2022Submission Checks Completed
01 Jul 2022Assigned to Editor
01 Jul 2022Review(s) Completed, Editorial Evaluation Pending
06 Jul 2022Editorial Decision: Accept
Aug 2022Published in British Journal of Clinical Pharmacology. 10.1111/bcp.15466